Scleritis is a severe, potentially sight threatening, inflammatory disease involving the ocular surface. Despite recent advances its treatment remains a difficult problem. Systemic immunosuppressive therapy with corticosteroids or immunosuppressive agents or both is usually required to control the disease.' Early therapeutic intervention is important to prevent ocular complications and to minimise the potential morbidity and mortality associated with underlying systemic disease.
Systemic corticosteroids in high dosage, either orally or in intravenous pulses, are widely accepted as an effective form of treatment in patients with severe scleritis.23 But this treatment is often associated with unacceptable side effects and does not always control scleral inflammation. The addition of immunosuppressive agents in patients with severe scleritis improves the ocular outcome and decreases the morbidity associated with systemically administered corticosteroids. 4 regimens.67 In the present study we report the therapeutic effect of cyclosporin in the treatment of severe scleritis.
Patients and methods
Seven patients with scleritis were referred for assessment and treatment of their disease to the Ocular Immunology Clinic at St Vincent's Hospital. All seven patients were examined by the authors before and during their treatment and were followed up at regular intervals. They were also assessed by an ophthalmologist and an immunologist. A detailed history was taken and physical examination performed as well as appropriate investigations to exclude the presence of an associated systemic disease. Prior to treatment all patients had active ocular disease and were receiving a variety of topical and systemic anti-inflammatory drugs. These had either failed to control the disease and/or were associated with unacceptable side effects.
All patients were started on cyclosporin 10 mg per kilogram body weight daily. After two to four weeks of therapy the dose of cyclosporin was incrementally decreased at one-to two-week intervals until a dose of 5 mg/kg or less was reached in each patient. Pulse methylprednisolone or oral steroids were continued at the current dose and other immunosuppressive agents were stopped. Pulse steroids were then 743 A subjective grading system,' analogous to that previously described for patients with uveitis and retinal vasculitis was used. A scleritis score was calculated when the patients first presented and at each follow-up visit. Improvement was defined as a decrease in the total score of greater than 2 and resolution at a total score of less than or equal to 4. Table 3, and Table 4 summarises the scleritis score for each patient at presentation and at twelve weeks after the commencement of treatment. In five patients there was a significant decrease in the scleritis score at six weeks. This decrese in the scleritis score was maintained over the subsequent observation period. The mean duration of treatment was 7-4 (SD 2-4) months. Table 5 summarises the present clinical status, complications of treatment, and duration of followup. The mean duration of follow-up was 8-4 months, with a minimum of four months. Cyclosporin was well tolerated by all but one patient, and only one patient developed side effects that warranted the cessation of therapy. The most common side effects were hirsutism, gum hypertrophy, tremor, hypertension, and mild nephrotoxicity. There were no associated opportunistic infections. Three patients suffered a relapse in their scleritis on attempted withdrawal of cyclosporin. In patients 2 and 5 disease activity recurred when the cyclosporin dosage was decreased below 5 mg/kg/day, while patient 7 relapsed when the cyclosporin dose was decresed to 3 mg/kg/day. In each case patients were treated with intravenous pulse methylprednisolone therapy and the cyclosporin dosage was increased to 10 mg/kg/day. Patients 5 and 7 responded to this medication with a significant improvement in symptoms and decrease in their scleritis score. Unfortunately patient 2 suffered a perforation of the globe in an area of extensive scleral necrosis and corneal thinning. There was severe disorganisation of the anterior segment and it was decided that enucleation was the most appropriate form of therapy.
There was no difference in clinical features, scleritis score at presentation, or complications between patients who responded to cyclosporin and those who failed to respond to this treatment.
Discussion
Five of the seven patients treated as part of this uncontrolled trial responded to the use of cyclosporin. All The widespread use of cyclosporin in the treatment of autoimmune disease has been limited by a concern for the potential side effects, especially its propensity to cause renal, hepatic, and lymphoproliferative disease. This study provides further evidence that such systemic side effects appear to be less prevalent in patients with inflammatory eye disease, in whom severe adverse rections appear to be less frequent, than those seen in patients treated to prevent organ rejection following transplantation.' Tremor, hirsutism, hypertension, and raised creatinine levels were all observed complications in our patients. Another problem associated with the use of cyclosporin was the propensity for the scleritis to relapse on attempted withdrawal of the drug. This has been previously observed in the treatment of other autoimmune diseases with cyclosporin and is not always preventable by slowly withdrawing the drug.
The results of the present study indicate that cyclosporin is a potentially useful drug in the treatment of severe scleritis refractory to other immunosuppressive regimens. Unfortunately it is not universally effective, is complicated by frequent, mild side effects, and may be associated with recurrence of disease on attempted drug withdrawal. Despite these limitations we consider that cyclosporin is a useful additional drug in the management of severe scleritis, and its therapeutic value in the treatment of this disease warrants further investigation.
